> ## Content Index
> Fetch the complete content index at: https://www.tidemetrix.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# China's Nankai Hecheng begins trial production of peptide synthesis resins
- URL: https://www.tidemetrix.com/chinas-nankai-hecheng-begins-trial-production-of-peptide-synthesis-resins/
- Published: 2026-11-17T10:00:11.000Z
- Updated: 2026-11-17T10:00:11.000Z
- Description: Nankai Hecheng is advancing production of peptide synthesis resins, including 2-CTC resin, potentially adding another Chinese source of critical raw materials. Commercial supply volumes and customer qualification remain unconfirmed.
- Author: TideMetrix Editorial
- Tags: Raw Materials, China, #brief, Nankai Hecheng

Chinese materials manufacturer Nankai Hecheng has begun trial production of solid-phase peptide synthesis (SPPS) resins at its Cangzhou operation, according to a November 10 report by *Hebei Daily*.

The company's Cangzhou subsidiary has developed three synthesis-support resins, including a new 2-CTC resin, with management reporting stable trial production.

These resins provide the solid support on which peptide chains are assembled during manufacturing. They are distinct from chromatography media used to purify peptides after synthesis.

The development forms part of a larger manufacturing project described as having planned annual capacity of 2,010 tonnes of medicinal resins and 10 tonnes of active pharmaceutical ingredients (APIs).

However, the 2,010-tonne figure covers a broader range of medicinal resins and does not represent confirmed peptide synthesis resin capacity. The report provides no breakdown of the quantities allocated to individual products.

Management described pilot-scale process development and repeatability testing conducted with a local research institute. The project's first phase includes three production workshops.

The reported trial production marks progress toward manufacturing scale-up, but the company has not disclosed commercial shipment volumes, customer qualification results or a timetable for full-scale production.

For peptide manufacturers seeking alternative sources of synthesis resins, the next milestones will be evidence of consistent commercial production, product specifications and customer qualification.

### Sources

- [Hebei Daily — Cangzhou project report, November 10, 2026](https://hbxw.hebnews.cn/news/640720.html?ref=tidemetrix.com)